Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Gains from Sales and Divestitures (2016 - 2025)

Ironwood Pharmaceuticals' Gains from Sales and Divestitures history spans 16 years, with the latest figure at $194488.0 for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures fell 75.77% year-over-year to $194488.0; the TTM value through Dec 2025 reached $194488.0, down 75.77%, while the annual FY2025 figure was $194488.0, 75.77% down from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 was $194488.0 at Ironwood Pharmaceuticals, down from $802800.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $1.7 million in Q4 2021 and bottomed at $71588.0 in Q4 2023.
  • The 5-year median for Gains from Sales and Divestitures is $802800.0 (2024), against an average of $818838.8.
  • The largest annual shift saw Gains from Sales and Divestitures crashed 94.61% in 2023 before it surged 1021.42% in 2024.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $1.7 million in 2021, then fell by 21.8% to $1.3 million in 2022, then plummeted by 94.61% to $71588.0 in 2023, then soared by 1021.42% to $802800.0 in 2024, then tumbled by 75.77% to $194488.0 in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Gains from Sales and Divestitures are $194488.0 (Q4 2025), $802800.0 (Q4 2024), and $71588.0 (Q4 2023).